Figure 4.

Use of anti-CMV antiviral therapy by type of prevention strategy. Anti-CMV therapy was considered ganciclovir and foscarnet; induction therapy was the period during which patients received the equivalent of twice-daily dosing of anti-CMV therapy. Only patients with proven CMV reactivation included. Total percentage was determined by days on anti-CMV therapy divided by total days alive during the first 100 days after transplantation. Whiskers equal 10th to 90th percentile, and solid dots equal outliers.